Innovation for dialysis has a major impact on the lives of patients with end stage kidney failure. The Biohybrid Kidney XB Program group is seeking partnerships with companies interested in co-developing membrane technology, (synthetic) cell technology, material sciences and micro electromechanical systems for (semi-) implantable artificial kidneys and similar devices.

BRAINS-2026 accelerates innovation for brain disorders by developing drug delivery methods, advanced brain models, and home monitoring. Involving patients, researchers, and industry, it aims for practical solutions, timely delivery of treatment, and improved quality of life, strengthening Dutch knowledge and healthcare. 

In this program healthcare organisations, knowledge institutions and technology companies from South Holland are brought together around the central question how labor-saving and -relieving technology can be optimized and deployed to ensure the quality and accessibility of care with fewer personnel.

FEMCURE aims to develop innovative diagnostics and targeted therapeutics to address the current 8-year diagnostic delay and lack of proper therapies for menstrual disorders due to uterine disorders or endometriosis. Timely, effective treatments will improve quality of life and fertility for millions of women, while reducing healthcare and societal costs.

FORESIGHT is transforming drug development by using advanced molecular imaging to track medicines in the body and identify the best treatment for each patient. This innovative approach makes drug development faster, more effective, and more personalized, helping to bring better treatments to those who need them most.

This PPP programme focuses on the major societal challenges surrounding cardiovascular health. The aim of the cardiovascular agenda is for cardiovascular health to be measurably better in 2030 than it is today, with the reduction of health inequalities in society as an important spearhead.

ImmuneHealth-4-All is a national public–private program that accelerates innovation for chronic immune mediated inflammatory diseases by working across disease boundaries. By translating shared immune mechanisms into diagnostics, therapies and monitoring tools, the program aims to improve patient outcomes while strengthening the Dutch life sciences and health ecosystem.

This research program aims to improve treatment for the most severe and persistent form of depression: treatment-resistant depression. Within an existing network of research institutes and mental healthcare centres, the industrial development of promising treatment strategies will be facilitated to generate a broad range of clinical innovations.

The IMPACT program aims to advance machine perfusion technologies for organ preservation, assessment, and repair. By collaborating with top institutions and private partners, it drives innovative solutions to improve organ viability, enhance regeneration, and reduce immunogenicity, strengthening the Netherlands' position as a global leader in transplantation.

The number of people with dementia in the Netherlands who live longer and without (in)formal care is growing rapidly. In addition, the staff shortage in healthcare is growing. The DEMTECH program focuses on technologies that promote self-management, making these people less dependent on external care.